YOLFTbeta
Clearmind Medicine Inc. Common Shares

Clearmind Medicine Inc. Common Shares

CMND · NASDAQ · Healthcare / Biotechnology

4.53USD-0.09 (-1.95%)

Price History

Full chart

Market Stats

Previous Close4.62
Open4.52
Day Range4.35 – 4.79
52-Week Range0.77 – 480.00
Volume3.42K
Market Cap2.73M
P/E (TTM)0.00
Forward P/E0.00
EPS-57.79
Dividend Yield0.00%
Beta-1.14
50-Day Avg1.50
200-Day Avg9.41

About

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Adi Zuloff-Shani Ph.D.
  • Employees0
  • Headquarters1220 West 6th Avenue, Vancouver, BC, Canada, V6H 1A5, USA
  • Websitehttps://www.clearmindmedicine.com

Leadership

  • Dr. Adi Zuloff-Shani Ph.D.Chief Executive Officer · b. 1967
  • Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPAChief Financial Officer · b. 1952
  • Prof. Mark Haden M.S.W.Vice President of Business Development · b. 1953
  • Ms. Mylene TouboulAccounting Manager
  • Ms. Mary-Elizabeth GiffordChief of Global Impact
  • Ms. Adi VaronController

Financials

Income Statement

Currency: USD2014-10-312015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Total Revenue000--0000000
Cost of Revenue000----2.53K119.62K57.43K51.07K49.36K
Gross Profit000-----2.53K-119.62K-57.43K-51.07K-49.36K
Operating Expense33.23K46.86K24.21K----3.61M8.88M6.24M5.69M5.62M
Operating Income-33.23K-46.86K-24.21K-6.53K-254.53K-105.28K-233.22K-3.61M-9.00M-6.29M-5.74M-5.67M
EBITDA----6.53K-254.53K-105.28K-233.22K-3.65M-9.75M-8.53M-4.79M-3.72M
Net Income-33.23K-46.86K-24.21K-6.53K-194.53K-105.28K-233.22K-3.66M-9.93M-8.61M-5.25M-3.86M
R&D------0635.40K4.42M1.53M1.37M2.05M
Interest Expense000---0446.44K20.76K10.89K36.16K19.54K

Balance Sheet

Currency: USD2014-10-312015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Total Assets12.79K2704.30K100.65K188.06K135.47K384.81K4.16M1.12M5.95M10.10M6.08M
Total Liabilities31.43K21.76K50.01K51.28K5.83K33.85K10.03K288.19K2.62M4.97M5.77M4.89M
Total Equity-18.64K-21.49K-45.71K49.36K182.24K101.63K374.78K3.87M-1.50M983.47K4.33M1.19M
Cash3.54K2704.30K79.86K56.17K522.51247.58K3.71M174.79K5.43M9.15M3.92M
Total Debt--------52.11K-73.97K1.78M
Net Debt----79.86K-56.17K-522-247.58K-3.71M-122.68K-5.43M-9.08M-2.14M

Cash Flow

Currency: USD2014-10-312015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Operating Cash Flow-28.01K-39.81K-15.37K-8.93K-80.48K-47.85K-198.50K-2.08M-5.06M-6.30M-6.76M-4.73M
Investing Cash Flow----18.42K-99.98K-7.59K-3.82K-184.03K-7.55K-26.23K-331.43K-541.97K
Financing Cash Flow34.08K36.53K19.40K130.00K158.54K598.70K449.39K5.39M694.52K11.66M8.71M2.62M
Capital Expenditure00018.42K99.98K7.59K7.51K169.38K7.55K000
Free Cash Flow----27.55K-180.46K-55.45K-206.01K-2.25M-5.06M-6.30M-6.76M-4.73M
Dividends Paid------000---
FCF to OCF---308.50%224.23%115.87%103.78%108.15%100.15%100.00%100.00%100.00%
Dividend Paid to FCF------0.00%0.00%0.00%---

Earnings

Report DateOct 31, 2021Jan 31, 2022Apr 30, 2022Jul 31, 2022Oct 31, 2022Jan 31, 2023Apr 30, 2023Jul 31, 2023Oct 31, 2023Jan 31, 2024Apr 30, 2024Jul 31, 2024Oct 31, 2024Mar 13, 2025Jun 12, 2025Sep 11, 2025Jan 20, 2026Jan 31, 2026Jun 15, 2026Sep 10, 2026
EPS Estimate--------------------
EPS Actual-19307.35-15824.06-22967.79-14305.95-14495.60-9524.72-6649.15-973.68-4575.59-360.55-111.67-235.28-82.97-0.24-0.16-9.84-5.03-33.17-6.78-0.57
Surprise--------------------
Timing--------------------

Key Statistics & Ratios

Market Cap2.73M
Enterprise Value-11.28M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.22
EPS-57.79
Book Value6.04
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-8.86M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-106.98%
Return on Assets-53.08%
Shares Outstanding3.37M
Shares Float3.37M
Beta-1.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
1.46%
Insiders
0.04%
Retail / Other
98.50%

Top Institutional Holders

  • Citadel Advisors Llc
    11.71K0.55%
  • XTX Topco Ltd
    21.69K0.10%
  • HRT FINANCIAL LLC
    15.91K0.07%
  • AdvisorShares Investments, LLC
    1.17K0.05%
  • Royal Bank of Canada
    140.00%
  • UBS Group AG
    10.00%
  • JPMorgan Chase & Co
    00.00%

Top Fund Holders

  • AdvisorShares Psychedelics ETF
    1.39K0.09%

Stock Splits

  • May 21, 20261:10
  • Dec 15, 20251:40
  • Nov 28, 20231:30